Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Kristall will settle the dispute with Mast-J germeister SE amicably

3/21/24 KLVZ

NCHP reported for 2023 by IFRS

3/21/24 NKHP

NCSP plans to increase container transshipment by 40% in five years

3/21/24 FESH

Fesco considers buying an airline for cargo transportation

3/21/24 FESH

Live with the founder of Metacraft

3/21/24 OTCI

Lenta intends to open at least 500 new stores in 2024

3/21/24 LENT

Henderson has reopened two showrooms in the new format

3/21/24 HNFG

En+ Group's investments in HPP construction may exceed ₽500 billion

3/21/24 ENPG

En+ Group expects the Blagoveshchensk wind farm to be included in the RES DPM

3/21/24 ENPG

Mostotrest reported for 2023 by RAS

3/21/24 MSTT